Business Context and Reporting Period
The filing is DanDrit Biotech USA, Inc.’s unaudited Form 10-Q for the three months ended September 30, 2015, although the request metadata identifies Lunai Bioworks Inc. DanDrit is a Delaware holding company whose Danish subsidiary develops dendritic-cell cancer vaccines, principally MelCancerVac (MCV) for colorectal cancer. The company reports no current product approval for general sale and limited compassionate-use activity.
The company changed its fiscal year-end from December 31 to June 30 in June 2015. It was a smaller reporting company and an emerging growth company.
Financial Condition and Results
| Metric | Three months ended September 30, 2015 | Comparable 2014 period |
|---|---|---|
| Revenue | $0 | $0 |
| Gross loss | $0 | $(143,495) |
| Operating expenses | $341,395 | $370,245 |
| Loss from operations | $(341,395) | $(513,740) |
| Other income/(expense) | $(32,820) | $(19,395) |
| Net loss | $(350,302) | $(535,243) |
| Basic and diluted loss per share | $(0.04) | $(0.07) |
| Cash used in operating activities | $(416,036) | $(477,019) |
Research and development expense was $101,759, compared with none in the prior-year quarter, primarily for Phase IIb/III MCV clinical-trial activities. General and administrative expense was $204,851, amortization was $3,937, and consulting expense was $30,848.
At September 30, 2015, cash was $1,048,120, compared with cash and escrowed cash of $1,474,134 at June 30, 2015. Working capital was $554,152, down from $910,522. Total assets were $1,731,045 and total liabilities were $1,014,023. Current liabilities included $101,229 of related-party notes, $517,544 of accounts payable, $375,702 of related-party accounts payable, and $19,548 of accrued expenses.
Stockholders’ equity was $717,022, including an accumulated deficit of $24,915,757. The company had 9,533,290 common shares outstanding, including 185,053 shares reserved for non-consenting shareholders and treated as issued and outstanding for accounting purposes.
Cash increased by $626,975 during the quarter, primarily because $1,052,989 was released from cash held in escrow. There were no financing proceeds during the quarter. The company reported no material off-balance-sheet arrangements.
Material Changes Versus the Prior Comparable Period
- Revenue remained at zero, but the prior-year period included $143,495 of cost of goods sold associated with lysate production; 2015 therefore had no gross loss.
- Operating expenses decreased 8% to $341,395, principally because 2014 included higher equity-offering, legal, and consulting costs.
- Research and development expense increased from zero to $101,759 as clinical-trial work progressed.
- Net loss improved by $184,941, or 35%, to $350,302, despite a $32,228 foreign-currency loss versus a small currency gain in 2014.
- Operating cash burn declined approximately 13% to $416,036, but the company remained dependent on external financing.
- Cash and working capital declined from June 30, 2015 because of operating expenditures, research and development spending, and financing-related efforts.
Guidance, Outlook, Risks, Contingencies, and Unusual Items
Management plans to continue raising capital, pursue MCV-related revenue opportunities, and advance planned Phase III testing. The company states that available cash, potential funding sources, and two July 2015 capital commitments of $1 million each are expected to fund anticipated needs for the next twelve months. The commitments expire July 10, 2016; the filing does not establish that either commitment had been funded as of September 30, 2015.
Management identifies substantial historical losses, insufficient working capital relative to projected losses and clinical-trial plans, lack of revenue, dependence on additional financing, and the need for regulatory approval as going-concern risks. Financing may be unavailable or available only on unfavorable terms. Future compassionate-use sales are not assured.
MCV remains subject to extensive clinical, manufacturing, and regulatory requirements, including potential FDA approval. Product-liability exposure, foreign-currency fluctuations, related-party obligations, and the ability to complete planned trials are additional risks. The company reported no material pending legal proceedings and no defaults on senior securities.
Related-party balances and transactions were significant. The company owed $375,702 to a law firm partially owned by the chairman and had $101,229 of related-party notes payable. It also reported related-party medical consulting and other consulting payments during the quarter.
Investor Verification Points
- Verify the issuer identity: the supplied filing is for DanDrit Biotech USA, Inc., not Lunai Bioworks Inc.
- Confirm whether the two $1 million capital commitments were legally binding, funded, and available to the company.
- Assess cash runway against the reported quarterly operating cash burn and planned Phase IIb/III and Phase III activities.
- Review the regulatory and clinical status of MCV, including the likelihood, timing, and funding of future trials and approvals.
- Reconcile the significant related-party payables, notes, consulting arrangements, and repayment terms.
- Evaluate the treatment and availability of the $1,052,989 escrow release and whether comparable cash sources will recur.
- Consider dilution risks from future equity financings and the 185,053 shares reserved for non-consenting shareholders.